These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 8840127

  • 1. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
    Maneuf YP, Nash JE, Crossman AR, Brotchie JM.
    Eur J Pharmacol; 1996 Jul 18; 308(2):161-4. PubMed ID: 8840127
    [Abstract] [Full Text] [Related]

  • 2. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
    Aceto MD, Scates SM, Lowe JA, Martin BR.
    Eur J Pharmacol; 1995 Aug 25; 282(1-3):R1-2. PubMed ID: 7498260
    [Abstract] [Full Text] [Related]

  • 3. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
    Järbe TU, Lamb RJ, Liu Q, Makriyannis A.
    Eur J Pharmacol; 2003 Apr 11; 466(1-2):121-7. PubMed ID: 12679148
    [Abstract] [Full Text] [Related]

  • 4. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.
    Maneuf YP, Brotchie JM.
    Br J Pharmacol; 1997 Apr 11; 120(8):1397-8. PubMed ID: 9113356
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
    Lay L, Angus JA, Wright CE.
    Eur J Pharmacol; 2000 Mar 10; 391(1-2):151-61. PubMed ID: 10720647
    [Abstract] [Full Text] [Related]

  • 6. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
    Massi P, Fuzio D, Viganò D, Sacerdote P, Parolaro D.
    Eur J Pharmacol; 2000 Jan 17; 387(3):343-7. PubMed ID: 10650181
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB, Nalwalk JW, Stadel R, Timmerman H, Leurs R, Paria BC, Wang X, Dey SK.
    J Pharmacol Exp Ther; 2002 Oct 17; 303(1):314-22. PubMed ID: 12235266
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus.
    Venderova K, Brown TM, Brotchie JM.
    Exp Neurol; 2005 Jul 17; 194(1):284-7. PubMed ID: 15899265
    [Abstract] [Full Text] [Related]

  • 9. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb 17; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 10. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
    Beardsley PM, Martin BR.
    Eur J Pharmacol; 2000 Jan 03; 387(1):47-53. PubMed ID: 10633159
    [Abstract] [Full Text] [Related]

  • 11. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
    Manzanares J, Corchero J, Fuentes JA.
    Brain Res; 1999 Aug 21; 839(1):173-9. PubMed ID: 10482810
    [Abstract] [Full Text] [Related]

  • 12. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA.
    Pharmacol Biochem Behav; 2001 Aug 21; 69(1-2):239-49. PubMed ID: 11420092
    [Abstract] [Full Text] [Related]

  • 13. Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice.
    da Silva GE, Morato GS, Takahashi RN.
    Eur J Pharmacol; 2001 Nov 16; 431(2):201-7. PubMed ID: 11728426
    [Abstract] [Full Text] [Related]

  • 14. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
    Gessa GL, Casu MA, Carta G, Mascia MS.
    Eur J Pharmacol; 1998 Aug 21; 355(2-3):119-24. PubMed ID: 9760025
    [Abstract] [Full Text] [Related]

  • 15. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices.
    Gifford AN, Samiian L, Gatley SJ, Ashby CR.
    Eur J Pharmacol; 1997 Apr 18; 324(2-3):187-92. PubMed ID: 9145770
    [Abstract] [Full Text] [Related]

  • 16. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
    Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR.
    J Pharmacol Exp Ther; 2003 Jul 18; 306(1):93-102. PubMed ID: 12660305
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA, Járai Z, Bátkai S, Kunos G.
    Eur J Pharmacol; 2001 Jul 06; 423(2-3):203-10. PubMed ID: 11448486
    [Abstract] [Full Text] [Related]

  • 18. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
    Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, Arthur DB, Wilson DM, Martin BR.
    Eur J Pharmacol; 1998 Sep 18; 357(2-3):139-48. PubMed ID: 9797029
    [Abstract] [Full Text] [Related]

  • 19. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice.
    Reche I, Fuentes JA, Ruiz-Gayo M.
    Eur J Pharmacol; 1996 Apr 22; 301(1-3):75-81. PubMed ID: 8773449
    [Abstract] [Full Text] [Related]

  • 20. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
    Acquas E, Pisanu A, Marrocu P, Goldberg SR, Di Chiara G.
    Eur J Pharmacol; 2001 May 11; 419(2-3):155-61. PubMed ID: 11426837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.